Atlas Venture Life Science Advisors, LLC Q2 2025 Filing
Filed August 12, 2025
Portfolio Value
$662.4B
Holdings
11
Report Date
Q2 2025
Filing Type
13F-HR
All Holdings (11 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 4,896,462 | $213.7B | 32.26% | |
| 2 | IRONDisc Medicine, Inc. | 2,384,456 | $126.3B | 19.07% | |
| 3 | DYNDyne Therapeutics, Inc. | 9,130,465 | $86.9B | 13.12% | |
| 4 | SIONSionna Therapeutics, Inc. | 3,694,020 | $64.1B | 9.68% | |
| 5 | THRDThird Harmonic Bio, Inc. | 10,402,286 | $56.5B | 8.53% | |
| 6 | VIGLVigil Neuroscience, Inc. | 5,836,874 | $46.4B | 7.01% | |
| 7 | DAWNDay One Biopharmaceuticals, Inc. | 6,430,257 | $41.8B | 6.31% | |
| 8 | KRROKorro Bio, Inc. | 1,137,149 | $14.2B | 2.14% | |
| 9 | —Ikena Oncology, Inc. | 5,018,178 | $6.7B | 1.02% | |
| 10 | QTTBQ32 Bio, Inc. | 2,092,106 | $3.1B | 0.47% | |
| 11 | GBIOGBXGeneration Bio, Co. | 8,279,484 | $2.7B | 0.40% |